{"pageContent": "Purpose of review: Immune checkpoint therapy has grown in prominence in the last few decades and is being increasingly utilized in treatment of advanced cancers. Although information on toxicities of these drugs is forthcoming, not much is known regarding the toxicity profile of these drugs from a sexual function standpoint. We undertook the current review to appraise the literature for endocrine/sexual side effects of anti-PD-1/PD-L1 and anti-CTLA-4 therapy.", "metaData": {"source": "'Potency': the validation of information from a self-administered questionnaire using objective measurements of night-time erections and test-retest reliability\nhttps://pubmed.ncbi.nlm.nih.gov/9467490/"}}